131
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

      research-article
      1 , 1 , 1 , 2 , 2 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 3 , 4 , 5 , 6 , 7 , 7 , 8 , 8 , 8 , 9 , 10 , 11 , 11 , 2 , 2 , 12 , 12 , 1 , 2 , 14 , 1 , 15 , 1
      Nature

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          The genetics of renal cancer is dominated by inactivation of the VHL tumour suppressor gene in clear cell carcinoma (ccRCC), the commonest histological subtype. A recent large-scale screen of ~3500 genes by PCR-based exon re-sequencing identified several new cancer genes in ccRCC including UTX (KDM6A) 1, JARID1C (KDM5C) and SETD2 2. These genes encode enzymes that demethylate ( UTX, JARID1C) or methylate ( SETD2) key lysine residues of histone H3. Modification of the methylation state of these lysine residues of histone H3 regulates chromatin structure and is implicated in transcriptional control 3. However, together these mutations are present in fewer than 15% of ccRCC, suggesting the existence of additional, currently unidentified cancer genes. Here, we have sequenced the protein coding exome in a series of primary ccRCC and report the identification of the SWI/SNF chromatin remodeling complex gene PBRM1 4 as a second major ccRCC cancer gene, with truncating mutations in 41% (92/227) of cases. These data further elucidate the somatic genetic architecture of ccRCC and emphasize the marked contribution of aberrant chromatin biology.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

          To evaluate the role of oncogenic RAS mutations in pancreatic tumorigenesis, we directed endogenous expression of KRAS(G12D) to progenitor cells of the mouse pancreas. We find that physiological levels of Kras(G12D) induce ductal lesions that recapitulate the full spectrum of human pancreatic intraepithelial neoplasias (PanINs), putative precursors to invasive pancreatic cancer. The PanINs are highly proliferative, show evidence of histological progression, and activate signaling pathways normally quiescent in ductal epithelium, suggesting potential therapeutic and chemopreventive targets for the cognate human condition. At low frequency, these lesions also progress spontaneously to invasive and metastatic adenocarcinomas, establishing PanINs as definitive precursors to the invasive disease. Finally, mice with PanINs have an identifiable serum proteomic signature, suggesting a means of detecting the preinvasive state in patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The SWI/SNF complex and cancer.

            The mammalian SWI/SNF complexes mediate ATP-dependent chromatin remodeling processes that are critical for differentiation and proliferation. Not surprisingly, loss of SWI/SNF function has been associated with malignant transformation, and a substantial body of evidence indicates that several components of the SWI/SNF complexes function as tumor suppressors. This review summarizes the evidence that underlies this conclusion, with particular emphasis upon the two catalytic subunits of the SWI/SNF complexes, BRM, the mammalian ortholog of SWI2/SNF2 in yeast and brahma in Drosophila, and Brahma-related gene-1 (BRG1).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A transposon-based genetic screen in mice identifies genes altered in colorectal cancer.

              Human colorectal cancers (CRCs) display a large number of genetic and epigenetic alterations, some of which are causally involved in tumorigenesis (drivers) and others that have little functional impact (passengers). To help distinguish between these two classes of alterations, we used a transposon-based genetic screen in mice to identify candidate genes for CRC. Mice harboring mutagenic Sleeping Beauty (SB) transposons were crossed with mice expressing SB transposase in gastrointestinal tract epithelium. Most of the offspring developed intestinal lesions, including intraepithelial neoplasia, adenomas, and adenocarcinomas. Analysis of over 16,000 transposon insertions identified 77 candidate CRC genes, 60 of which are mutated and/or dysregulated in human CRC and thus are most likely to drive tumorigenesis. These genes include APC, PTEN, and SMAD4. The screen also identified 17 candidate genes that had not previously been implicated in CRC, including POLI, PTPRK, and RSPO2.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                15 November 2010
                19 January 2011
                27 January 2011
                27 July 2011
                : 469
                : 7331
                : 539-542
                Affiliations
                [1 ] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
                [2 ]NCCS-VARI Translational Research Laboratory, National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore
                [3 ] Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
                [4 ]Bioinformatics and Statistics, Department of Molecular Biology, The Netherlands Cancer Institute. Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
                [5 ]Génétique Oncologique EPHE-INSERM U753, Faculté de Médecine Paris-Sud and Institut de Cancérologie Gustave Roussy, 94805 Villejuif
                [6 ]Centre Expert National Cancer Rares INCa “PREDIR“, Service d'Urologie, Hôpital de Bicêtre, AP-HP, 94276 Le Kremlin- Bicêtre, France
                [7 ]Department of Urology, Spectrum Health Hospital, Grand Rapids, Michigan 49503, USA.
                [8 ]Li Ka Shing Centre, Cambridge Research Institute, Cancer Research UK, Robinson Way, Cambridge CB2 0RE, UK
                [9 ]Bioinformatics, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
                [10 ]Institut für Theoretische Physik, Universität zu Köln, Zülpicherstr. 77,50937 Köln, Germany
                [11 ]Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
                [12 ]Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA.
                [13 ] Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA.
                [14 ]Laboratory of Cancer Therapeutics, DUKE-NUS Graduate Medical School, Singapore
                [15 ]Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
                Author notes
                Correspondence and requests for materials should be addressed to BTT ( Bin.Teh@ 123456vai.org ), MRS ( mrs@ 123456sanger.ac.uk ) or PAF ( paf@ 123456sanger.ac.uk ).

                Author contribution

                IV and PT performed the main analytical aspects of the study. PS, HD, GLD, M-LL, GB, CH, LM, SM performed the follow-up sequencing and analyses. KR, DJ, JT, AB, CG, DG, MJ, CL, JM, AM, LS contributed to the data processing, mapping and variant calling informatics. CG and KWL performed statistical analyses. SR, RJK, JA contributed samples and data for the clinical series. DJA, AR, DAL, LFAW, DAT, PAP-M performed the transposon screening and analyses. DH, CKO, WC, CS performed the siRNA and functional work. VM, AF performed the missense mutation analysis. KD, KF and JC performed the expression analyses. PJC, BTT, MRS, PAF directed the study and wrote the manuscript, which all authors have approved.

                Article
                UKMS33194
                10.1038/nature09639
                3030920
                21248752
                3c002302-f092-4df8-a56f-6f3494f94898

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: Wellcome Trust :
                Award ID: 093867 || WT
                Funded by: Wellcome Trust :
                Award ID: 088340 || WT
                Funded by: Wellcome Trust :
                Award ID: 077012 || WT
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article